GIST Support International - logo

GIST Support International - GIST In the News
GIST Imagery
Free-access GIST reviews
Read More
GIST Summit webcasts
Read More
Sutent and Thyroid Function
Read More
Managing Sutent side effects
Read More
New Italian GIST group
Read More
Warning: Gleevec heart effects
Read More
Dr. von Mehren on GIST

Read More

PET Scans & Medicare
Read More
Cardiotoxicity from imatinib?
Read More
GSI attends ASCO
Read More
Sutent approved in Canada
Read More
ESMO GIST/Sarcoma meeting
Read More
Sarcoma Awareness Week
Read More
Novartis GIST Registry
  Read More
4-year follow-up of Gleevec
Saturday, February 04, 2006 Read More
Phase I Clinical Trial of IPI-504

This new drug is entering a Phase I trial at Dana Farber Cancer Center for patients with GIST who have progressed on Gleevec. Trial participants may have tried other drugs besides Gleevec.

Read More
Sutent benefits over half of trial patients
Clinical trial shows SU11248 benefits more than half of patients with gastrointestinal tumors resistant to Gleevec.  This news story from Dana-Farber summarizes the Sutent study presented at ASCO 2005 (see our webcasts page). Read More
ECCO 13 - Sunitinib prolongs survival in GIST patients after imatinib mesylate failure
This is a news story from Eurekalert concerning Sutent results presented at the 13th European Cancer Conference, November 3, 2005. Read More
Pfizer submits application to FDA for Sutent (SU11248)
NEW YORK, August 10 -- Pfizer Inc said today that it has submitted a New Drug Application for its cancer medicine SU11248 (sunitinib malate), known as Sutent, to the U.S. Food and Drug Administration. Read More
patientINFORM
This new service to summarize medical research for patients will be up and running soon. Read More


back to top